Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2017-08-31

FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Alvogen, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Levothyroxine Sodium from Alvogen, Inc., resulting in labeling changes for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVOTHYROXINE SODIUM (levothyroxine sodium)

Snippet

SUPPL AP for LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)